Cytokinetics Shares Jump 16% After WSJ Report of Novartis Deal
08 Enero 2024 - 12:43PM
Noticias Dow Jones
By Ben Glickman
Shares of Cytokinetics jumped Monday after the Wall Street
Journal reported the company was close to being bought by
Novartis.
The stock was up 16% to $109.22 after the news broke, reversing
declines earlier in the day. Shares have more than doubled in the
last year.
A deal could be finalized as soon as this week, people familiar
with the situation told WSJ. Cytokinetics has been running a sale
process and another buyer could potentially emerge.
Novartis shares were down 0.4% to $105.90.
Cytokinetics shares surged last month after releasing positive
data for a potential treatment for hypertrophic cardiomyopathy, a
genetic heart condition.
Write to Ben Glickman at ben.glickman@wsj.com
(END) Dow Jones Newswires
January 08, 2024 13:28 ET (18:28 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
Novartis (NYSE:NVS)
Gráfica de Acción Histórica
De Abr 2024 a May 2024
Novartis (NYSE:NVS)
Gráfica de Acción Histórica
De May 2023 a May 2024